GLP-1 Drugs: The Cycle of Weight Loss and Regain

A significant number of patients using GLP-1 medications for weight loss or diabetes are discontinuing their treatment prematurely, with less than a quarter remaining on the drugs after one year. This trend is influenced by factors such as high costs, loss of insurance coverage, and side effects, as well as a perception that these treatments are temporary.

Despite these interruptions, many individuals plan to resume taking these medications, suggesting a pattern of cycling on and off GLP-1s. This cyclical usage is becoming more common, partly due to increased availability of pills and online sales channels that bypass traditional healthcare routes.

Research indicates that weight lost through GLP-1s may be regained more rapidly after cessation compared to other weight management strategies. Furthermore, experts caution that this intermittent use could lead to a substantial loss of lean muscle mass, potentially up to 40% of total weight lost. This muscle loss can manifest visibly, sometimes referred to as "Ozempic face."

Concerns are mounting regarding the long-term effects of reduced muscle mass, which can impact balance, mobility, and overall metabolism. This is particularly worrying for older populations who are already prone to age-related muscle decline, increasing their risk of falls and fractures. The cumulative effect on the body's muscle-to-fat ratio from this cycling is still under investigation.